Loading...
Syntaxin appoints Executive Chairman
01-Oct-2009
- United Kingdom
Advertisement
Syntaxin, a biopharmaceutical company developing novel biologic drugs that control cell secretion, reports that Andrew Sandham has been appointed Executive Chairman. This follows the resignation of CEO, Patrick Doyle, for personal reasons. Mr Sandham has worked closely with Syntaxin since its formation in 2005, as chairman of the board. A search has been initiated for the vacant position of CEO.